纤维性肾小球肾炎:多机构队列的临床病理特征与非典型病例
该多机构回顾性队列纳入1997至2017年266例纤维性肾小球肾炎(FGN)或疑似FGN的肾活检病例,约11%存在单克隆沉积、刚果红阳性或异常纤维直径等非典型特征。DNAJB9免疫染色在确诊FGN中100%阳性、疑似病例中79%阳性。中位24个月随访(n=100)中53%达到ESKD或死亡复合终点,男性及基线eGFR低是主要预测因素,利妥昔单抗与疾病稳定相关。
要点
- DNAJB9免疫染色有助于诊断非典型纤维性肾小球肾炎。
- 纤维性肾小球肾炎预后差,基线肾功能不全和男性提示进展风险高。
- 利妥昔单抗可能有助于特定患者维持肾功能。
核心结论
- DNAJB9检测有助于诊断非典型形式的纤维性肾小球肾炎。
- 纤维性肾小球肾炎预后差,进展至ESKD主要受诊断时肾功能不全程度和男性性别影响。
- 利妥昔单抗可能帮助特定纤维性肾小球肾炎患者维持肾功能。
研究设计与样本
- 多机构回顾性队列研究,回顾1997至2017年诊断为纤维性肾小球肾炎或疑似纤维性肾小球肾炎的肾活检(n=266,65%女性,中位年龄61岁)。
主要发现
- 约11%的肾活检有一个或多个不寻常特征,包括单克隆沉积、刚果红阳性或异常纤维直径。
- 作为可能的具有肾脏意义的单克隆丙种球蛋白病的纤维性肾小球肾炎占病例<1%。
- DNAJB9免疫染色在诊断为纤维性肾小球肾炎的病例中100%确认,在诊断为可能纤维性肾小球肾炎的非典型病例中79%确认。
- 活检后中位24个月(四分位距8-46个月,n=100),53%患者达到ESKD或死亡的复合主要结局,18%有CKD,18%部分缓解。
- 多变量分析中,男性(调整风险比[aHR] 3.82;95%置信区间[95%CI] 1.97至7.37)和eGFR是主要结局的最显著预测因素(eGFR<30 ml/min per 1.73 m2时aHR 8.02 [95%CI 1.85至34.75];eGFR 30至<45 ml/min per 1.73 m2时aHR 6.44 [95%CI 1.38至29.99])。
临床怎么用
- 对疑似纤维性肾小球肾炎尤其非典型病例,应行DNAJB9免疫染色辅助诊断。
- 诊断时评估eGFR和性别有助于风险分层,eGFR<30或30-<45 ml/min per 1.73 m2者进展风险高。
- 利妥昔单抗可考虑用于特定纤维性肾小球肾炎患者以稳定疾病进展。
局限性
- 回顾性研究设计。
- 随访数据仅100例可评估主要结局,样本量有限。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND OBJECTIVES: Fibrillary GN has been defined as an immune complex-mediated GN with amyloid-like fibrils larger than amyloid which are IgG positive and Congo red negative. With discovery of DNAJB9 as a highly sensitive and specific marker for fibrillary GN, the specificity of the morphologic criteria for establishing the diagnosis of fibrillary GN has come into question. DESIGN, SETTING, PARTICIPANTS, & MEASUREMENTS: We sought to (1) determine anatomic characteristics that best define fibrillary GN and (2) identify clinical and pathologic features that predict outcomes. RESULTS: We retrospectively reviewed kidney biopsies from patients diagnosed with fibrillary GN or suspected fibrillary GN between 1997 and 2017 (n=266, 65% female, median age 61). Approximately 11% of kidney biopsies had one or more unusual feature including monotypic deposits, Congo red positivity, or unusual fibril diameter. Fibrillary GN as a possible monoclonal gammopathy of renal significance represented <1% of cases. Immunostaining for DNAJB9 confirmed fibrillary GN in 100% of cases diagnosed as fibrillary GN and 79% of atypical cases diagnosed as possible fibrillary GN. At a median time of 24 months (interquartile range, 8-46 months) after biopsy (n=100), 53% of patients reached the combined primary outcome of ESKD or death, 18% had CKD, and 18% had partial remission. On multivariable analysis, male sex (adjusted hazard ratio [aHR], 3.82; 95% confidence interval [95% CI], 1.97 to 7.37) and eGFR were the most significant predictors of primary outcome (aHR of 8.02 if eGFR <30 ml/min per 1.73 m2 [95% CI, 1.85 to 34.75]; aHR of 6.44 if eGFR 30 to <45 ml/min per 1.73 m2 [95% CI, 1.38 to 29.99]). Immunosuppressive therapy with rituximab was significantly associated with stabilization of disease progression. CONCLUSIONS: Detection of DNAJB9 is a useful diagnostic tool for diagnosing atypical forms of fibrillary GN. The outcomes for fibrillary GN are poor and progression to ESKD is influenced predominantly by the degree of kidney insufficiency at the time of diagnosis and male sex. Rituximab may help preserve kidney function for select patients with fibrillary GN. PODCAST: This article contains a podcast at https://www.asn-online.org/media/podcast/CJASN/2019_11_04_CJN03870319.mp3.
引用
- Andeen NK, Troxell ML, Riazy M, et al. Fibrillary Glomerulonephritis: Clinicopathologic Features and Atypical Cases from a Multi-Institutional Cohort. Clin J Am Soc Nephrol. 2019. PMID: 31685544. doi:10.2215/CJN.03870319
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。